Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
7/24/2024 | $36.00 | Buy | ROTH MKM | |
7/17/2024 | Speculative Buy | Canaccord Genuity | ||
5/29/2024 | $27.00 | Outperform | Robert W. Baird | |
4/15/2024 | $20.00 | Outperform | Leerink Partners | |
4/5/2024 | $2.25 → $2.75 | Neutral | Alliance Global Partners | |
2/9/2024 | Hold → Buy | Canaccord Genuity | ||
12/5/2023 | $9.00 | Buy | Canaccord Genuity | |
4/4/2023 | Underperform → Mkt Perform | Bernstein |
4 - Cronos Group Inc. (0001656472) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Canopy Growth Corp (0001737927) (Issuer)
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla
Canopy Growth's AGM to be held in a virtual-only format on Tuesday, September 24, 2024 at 1:00 PM ET.Voting is important and easy; shareholders are encouraged to vote now.Canopy Growth shareholders with a 16-digit control number can vote online at http://proxyvote.com, by phone at 1-800-474-7493, and by mail using the enclosed pre–paid envelope.For more information, shareholders should contact Canopy Growth's strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, at 1-877-452-7184 (1–416–304–0211 for collect calls outside North America) or by email at [email protected] FALLS, ON, Aug. 13, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy G
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Aug. 23, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated. Q2 2024 Financial Highlights 12% Revenue increase to $14.8M vs. $13.2M in Q2 2023 129% increase in IMC Germany sales vs. Q2 2023 to $3.5M. IMC Germany sales now make up 24% of the entire Company r
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024-- --Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025-- --New patent issued by the United States Patent and Trademark Office (USPTO) extends intellectual property protection for MM120 ODT through 2041-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a
SC 13D/A - IGC Pharma, Inc. (0001326205) (Subject)
SC 13D - IGC Pharma, Inc. (0001326205) (Subject)
SC 13D/A - Cronos Group Inc. (0001656472) (Subject)
Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company's local EU GMP facility in Leuna, Germany.
California's Glass House Reappoints Board Member As Benzinga Cannabis Capital Conference returns to Chicago this Oct. 8-9 for its 19th edition, gathering top CEOs, investors investors and leaders in the cannabis industry, let’s scroll through the latest leadership changes in the space. Get your tickets now before prices surge by following this link. Long Beach, California-based vertically-integrated cannabis company Glass House Brands Inc. (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX:GLASF) (OTCQX:GHBWF) announced last week the reappointment of Hector De La Torre to its board of directors. De La Torre previously served as an original member of the board until 2023. At the time, he s
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 117.39% at $0.04 CordovaCann (OTC:LVRLF) shares closed up 19.90% at $0.06 SOL Glb Inv (OTC:SOLCF) shares closed up 19.40% at $0.06 1933 Industries (OTC:TGIFF) shares closed up 11.81% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.37% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 6.01% at $0.04 22nd Century Group (NASDAQ:XXII) shares closed up 4.77% at $0.72 EnWave (OTC:NWVCF) shares closed up 4.53% at $0.17 Psychemedics (NASDAQ:PMD) shares closed up 3.52% at $2.24 cbdMD (AMEX:YCBD) shares closed up 3.11% at $0.63 LOSERS: Green Growth Brands (OTC:GGBXF) shares closed down 99.00% at $1e-06 Leafbuyer Techs (OTC:LBUY)
ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00
Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy
Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00
IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following the FDA's 2023 approval of two groundbreaking anti-amyloid drugs, Donanemab (Eli Lilly) and Lecanemab (Eisai and Biogen), IGC Pharma is poised to make a significant contribution to this critical field with IGC-AD1. The recognition of amyloid-targeted therapies in slowing Alzheimer's progression and improving cognitive function underscores the growing demand for innovative treatments. While the recent drug approvals have been a signific
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Format: Panel Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders Date and Time: Tuesday, September 10, 2024 at 3:00 PM ET Location: New York, NY Baird's 2024 Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, September 11, 2024 at 12:15 PM ET Location: New
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
6-K - SNDL Inc. (0001766600) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
DEFA14A - Canopy Growth Corp (0001737927) (Filer)